Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Annual pharma and biotech R&D spending remained largely flat from 2008 to 2010 at about $130 billion, per EvaluatePharma.
Although the FDA approves an average of half a hundred new drugs every year, few are really called to obtain large sales in the market. In fact, the consultant Evaluate…
The British company EvaluatePharma, which broadly aggregates analysts' estimates, expects the pharmaceutical industry to generate around $ 50 billion in additional sales…
Keytruda is well on the way to becoming the most profitable drug in the world within a few years.
By 2022 the global market will break the billion dollar barrier. In 2024 it will reach $1.18 billion (1.04 billion euros), according to a report by the consultant…
Being far behind the competition and not yet having secured US approval has not prevented the drug from attracting a $1.3 billion 2024 sales forecast, according to…
The anticancer Keytruda should soon climb to first place on the podium. Its turnover could cross the 20 billion dollar mark in 2023 and reach 22 billion the following…
According to Evaluate Pharma’s 2020 Preview report published in December, Eliquis ranks as the No.4 biggest new sales generator, with a projected sales increase of $1.08…
Allergan’s Ubrelvy, formerly known as ubrogepant, passed FDA gatekeepers Monday, becoming the first oral CGRP drug for the acute treatment of migraines….EvaluatePharma…
Zepsyre carries 2024 sales forecasts of $163 million, implying an NPV of $600 million, according to EvaluatePharma.